

MAJOR SHAREHOLDER LOAN FOR \$5 MILLION

Highlights

- \$5 million loan secured to advance the Dimerix Phase 3 clinical programs in FSGS, including clinical site start up activities and regulatory agency interactions

MELBOURNE, Australia, 30 March 2021: Dimerix Limited (ASX: DXB), a clinical-stage drug development company, is pleased to announce that it has entered into an unsecured loan agreement (Loan Agreement) with 13.4% shareholder, Mr Peter Meurs.

Under the Loan Agreement, Mr Meurs has agreed to advance \$5 million to the Company, providing a non-dilutive cash runway on terms more favourable to the Company than other available loan facilities and delivers funding for Dimerix to progress current initiatives. Most notably is the preparation for the upcoming Phase 3 Focal Segmental Glomerulosclerosis (FSGS) study, including the clinical study start up activities with a global Clinical Research Organisation (CRO) and the protocol agreement with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

"We are extremely grateful for the ongoing support and confidence shown by the Company's largest shareholder in DMX-200 and the Company's future. The recent FSGS Phase 2 clinical data, as well as our participation in two different multi-national Phase 3 studies in patients with COVID-19, underlines our belief in the potential for DMX-200 to become a major new drug in the treatment of inflammatory diseases.

To better position Dimerix to execute on this very exciting opportunity, we have taken steps to boost our balance sheet with a secure and non-dilutive cash injection to take us through to the next key inflection point. With our core team now in place, and the consistent and growing evidence of DMX-200 in these inflammatory diseases, we are in a great position to maximise shareholder value."

Dr Nina Webster, CEO & Managing Director, Dimerix

The loan will be received within 5 days, accruing interest at the compounded rate of 1% per month with a repayment date of the earlier of 31 December 2021, or in the event of a funding event such as a capital raise or other transaction exceeding \$10 million, or receipt of R&D rebate exceeding \$5 million.

The Company reported a cash position of \$4.9 million as at 31 December 2020.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product, DMX-200, for Diabetic Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) and Acute Respiratory Distress Syndrome (ARDS), and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving irbesartan, an angiotensin II type I (AT1) receptor blocker and the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032.

In 2017, Dimerix completed its first Phase 2a study in patients with a range of chronic kidney diseases. No significant adverse safety events were reported, and all study endpoints were achieved. The compelling results from this study prompted the decision to initiate two different clinical studies in 2018: one for patients with Diabetic Kidney Disease; and the second for patients with another form of kidney disease, Focal Segmental Glomerulosclerosis (FSGS). DMX-200 is also under investigation as a potential treatment for acute respiratory distress syndrome (ARDS) in patients with COVID-19.

About DMX-700

Chronic Obstructive Pulmonary Disease (COPD) is a progressive and life-threatening lung disease. The most common cause of COPD is exposure to tobacco smoke (either active smoking or secondary smoke) however, COPD is also caused by exposure to indoor and outdoor air pollution, occupational dusts and fumes and long-term asthma. COPD is the fourth-leading cause of death in the world and although treatments exist to improve the symptoms of COPD, there is currently no way to slow progression of the condition or cure it. Moreover, among the top five causes of death globally, this disease is the only one with increasing mortality rates. In 2016, the Global Burden of Disease Study reported a prevalence of 251 million cases of COPD globally, and it was estimated that 3.17 million deaths were caused by the disease in 2015, which equates to 5% of all deaths globally in that year (WHO Factsheet – Chronic Obstructive Pulmonary Disease). The global COPD treatment market was valued at US\$14 billion in 2017 and is projected to increase at a compound annual growth rate of 4.9% to 2026.